Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 19Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

Etoposide 3etoposide phosphate 2Paclitaxel 2Ifosfamide 2Cisplatin 2tremelimumab 1pembrolizumab 1durvalumab 1cabozantinib 1Sirolimus 1Quality of Life 1Proton Therapy 1Mesna 1Granulocyte Colony-Stimulating Factor 1Cyclophosphamide 1Celecoxib 1Carboplatin 1Bleomycin 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Germ Cell and Embryonal × cabozantinib × Clear all
NCT04876456 2026-01-15

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Indiana University

Phase 2 Active not recruiting
50 enrolled

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡